Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

How the Exposome Shapes Our Respiratory Health.

American journal of respiratory and critical care medicine·2026

Same author

Use of the Wnt/β-catenin Activator Lithium Is Associated with Less Emphysema.

Annals of the American Thoracic Society·2026

Same author

Spatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD.

Biomarker research·2026

Same author

Body mass index and airway mucus plugs: findings from the COPDGene and ECLIPSE studies.

Thorax·2026

Same author

Lobar Lung Density Embeddings with a Transformer encoder (LobTe) to predict emphysema progression in COPD.

Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention·2026

Same author

Blood vessels as primary site of rejection in murine lung transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2026

Same journal

Signal in the Noise: Polygenic Scores and the Problem of Defining Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026

Same journal

Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC?

American journal of respiratory and critical care medicine·2026

Same journal

Short for Their Age: Interpreting Whole-Genome Telomere Length in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026

Same journal

Association of a Polygenic Risk Score with Diagnosis and Outcomes in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026

Same journal

Reply to Qu et al.: Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC?

American journal of respiratory and critical care medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

Lung Fixation under Constant Pressure for Evaluation of Emphysema in Mice

Lung Fixation under Constant Pressure for Evaluation of Emphysema in Mice

Published on: September 26, 2019

Post-COPD: Can Emphysema Be Repaired?

J Michael Wells^1,2,3, Jerry A Krishnan^4,5, R Chad Wade^1,2,3

¹Division of Pulmonary, Allergy, and Critical Care Medicine and.

American Journal of Respiratory and Critical Care Medicine

|June 11, 2025

Summary

This summary is machine-generated.

Lung repair in humans is possible, with identified pathways and new clinical trial designs enabling emphysema treatment studies. Researchers can now test existing medications for their potential to regenerate alveolar structures and improve lung function.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Related Experiment Videos

Last Updated: Jun 13, 2025

Lung Fixation under Constant Pressure for Evaluation of Emphysema in Mice

Lung Fixation under Constant Pressure for Evaluation of Emphysema in Mice

Published on: September 26, 2019

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Area of Science:

Pulmonary Medicine
Regenerative Medicine
Clinical Trials

Background:

Clinical observations suggest the feasibility of alveolar structure repair or regeneration in humans.
Biological pathways governing lung repair have been identified in preclinical models and validated in human lung tissue.

Purpose of the Study:

To assess the scientific premise of lung repair in human emphysema through clinical trials.
To leverage advancements in imaging, functional studies, and biomarkers for sensitive outcome measurement.
To utilize innovative platform clinical trial designs for simultaneous drug and biomarker testing.

Main Methods:

Characterization of lung repair pathways in vivo and ex vivo models.
Validation of major biological pathways in adult human lung tissue.
Development of sensitive measures for treatment effects and clinical outcomes in emphysema.
Implementation of platform clinical trial designs for heterogeneous populations.

Main Results:

Major biological pathways involved in lung repair are validated in human lung tissue.
Sensitive measures for assessing treatment effects in emphysema are available.
Platform clinical trials allow for simultaneous testing of multiple drugs and biomarkers.

Conclusions:

The assessment of lung repair in human emphysema is feasible within clinical trials.
Approved medications targeting lung repair pathways offer potential therapeutic options for emphysema.
Advancements in trial design and outcome measures facilitate the study of emphysema regeneration.